Stocktoria
Unicycive Therapeutics, Inc. UNCY
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-06-17
Unicycive Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $675,000 | $951,000 | — |
| R&D expense | $9.1M | $20.0M | $12.9M | $12.4M | $6.1M |
| SG&A expense | — | — | — | $383,000 | $245,000 |
| Operating income | -$29.5M | -$32.1M | -$20.8M | -$18.1M | -$9.0M |
| Interest expense | — | — | $82,000 | $6,000 | $628,000 |
| Net income | -$26.6M | -$36.7M | -$30.5M | -$18.1M | -$10.0M |
| EPS (diluted) | $-1.67 | $-5.65 | $-1.28 | $-1.20 | $-0.86 |
| Operating cash flow | -$31.3M | -$28.6M | -$18.3M | -$15.7M | -$5.8M |
| Free cash flow | -$31.3M | -$28.6M | -$18.3M | -$15.7M | -$5.8M |
| Cash & equivalents | $29.2M | $26.1M | — | $455,000 | $16.6M |
| Inventory | — | — | — | $2.2M | $1.8M |
| Total assets | $49.1M | $31.7M | $14.2M | $2.8M | $18.7M |
| Total liabilities | $18.9M | $24.2M | $18.0M | $3.3M | $2.3M |
| Shareholders' equity | $30.2M | $7.4M | -$3.8M | -$466,000 | $16.5M |
Source: SEC EDGAR filings · CIK 0001766140 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.